Azvudine - Wikipedia
Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. [3] It was discovered for the treatment of hepatitis C [4] and has since been investigated for use against other viral …
Oral Azvudine for hospitalised patients with COVID-19 and pre …
A randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study
阿兹夫定 - 百度百科
阿兹夫定（Azvudine），又称阿滋福啶，由常俊标教授发明，河南真实生物科技有限公司、郑州大学、河南师范大学、河南省科学院高新技术研究中心共同研发。
阿兹夫定 - 维基百科，自由的百科全书
阿兹夫定 （简称 FNC）是 中国大陆 河南真实生物科技有限公司 研发的 抗病毒药物，用于治疗 艾滋病 [3] 和 2019冠状病毒病 [4]。 此物属 核苷类 （英语：Nucleoside analogue） 小分子药 …
使用国产新冠口服药「阿兹夫定」，这些要点需要了解！ - 丁香园
2023年1月4日 — 阿兹夫定（Azvudine） 是新型核苷类逆转录酶和辅助蛋白 Vif（Viral infectivity factor）双靶点抑制剂，是我国拥有完全自主知识产权并拥有全球专利的抗病毒 1.1 类创新药 …
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in …
2021年12月6日 — Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have …
Efficacy and safety of azvudine in patients with COVID-19: A …
2023年9月14日 — Azvudine can significantly increase the proportion of patients with improved clinical symptoms of COVID-19 within 5 days of treatment and achieve excellent clinical …
Azvudine (FNC): a promising clinical candidate for COVID-19
2020年10月10日 — To evaluate the efficacy and safety of FNC in patients with mild and common COVID-19, we recently conducted a randomized, open-label, controlled clinical trial of FNC …
A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets ...
Thus, this randomized, open-label, controlled clinical trial (ChiCTR2000029853) was performed in China. A total of 20 mild and common COVID-19 patients were enrolled and randomly …
A very recent work published in Advanced Science by our group reveals that 2′-deoxy-2′-β-fluoro-4′-azidocytidine (Azvudine, FNC), a clinical candidate originally developed for HIV treatment, …